se of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumour (NET) patients in Germany – A retrospective evaluation in German centers for NET
- Conditions
- Confirmed diagnosis of GEP-NET (any localization of the primary tumour including CUP , any Grade)
- Registration Number
- DRKS00031054
- Lead Sponsor
- ovartis Radiopharmaceuticals GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Confirmed diagnosis of GEP-NET (any localization of the primary tumour including CUP2, any Grade)
First cycle of primary PRRT of home-brew 177Lu-DOTATATE/DOTATOC or Lutathera® between 01st July 2020 and 30th June 2021
Exclusion Criteria
Combination of PRRT with chemotherapy
Combination of PRRT with a radionuclide other than lutetium-177 (e.g., yttrium-90).
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Due to the non-interventional nature of this study, the definition of endpoints as primary or secondary is omitted formally.<br>The following clinical endpoints will be assessed descriptively:<br>Exploratory effectiveness endpoints<br>•Overall survival (OS) <br>•Progression free survival (PFS) <br>•Time to tumour progression (TTP)<br>•Objective response rate (ORR)<br>•Time to next treatment (TTNT)
- Secondary Outcome Measures
Name Time Method